News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
INNOVENT BIO Hyped Up 16%+; UBS Cites Firm Expecting Breakeven This Yr, Industry Top Pick Reiterated
INNOVENT BIO (01801.HK) opened nearly 6.1% higher this morning (4th) and once climbed to an intraday high of HKD76.95 with a surge of 18.3%. It last traded at HKD76.1, up nearly 17...
Reset
Send
The window will close in 5 seconds
INNOVENT BIO Hyped Up 16%+; UBS Cites Firm Expecting Breakeven This Yr, Industry Top Pick Reiterated
Close
Recommend
8
Positive
10
Negative
5
 
SHORT SELL
 
STOCK INFO

INNOVENT BIO (01801.HK)  +0.850 (+1.176%)    Short selling $121.31M; Ratio 6.982%   opened nearly 6.1% higher this morning (4th) and once climbed to an intraday high of HKD76.95 with a surge of 18.3%. It last traded at HKD76.1, up nearly 17%, on a turnover of HKD2.69 billion.

INNOVENT BIO narrowed its loss to RMB94.63 million last year. UBS issued a report on Monday (2nd) saying that the company expects to reach breakeven this year, and that it will prioritize partnerships with multinational companies to develop the global market for "PD-1/IL-2a".

Related NewsCCBI Expects HSI to Fluctuate Between 22,000/ 26,000 in 2H25, Suggests Investors to Accumulate Positions on Dips in 3Q
UBS reiterated INNOVENT BIO as its industry top pick, with a Buy rating remaining in place.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.